Clinical Trials Browser

Has announcements × Hodgkin Disease × Brentuximab Vedotin × Clear all

NCT03907488 2026-06-01

Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma

Phase 3 Active not recruiting

994 enrolled 11 charts 1 FDA

Hodgkin Disease

NCT02684292 2026-02-18

MK-3475-204

Phase 3 Completed

304 enrolled 1 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Hodgkin Disease